

**LINO J. DeGUZMAN, M.D.**

**PERSONAL**

**Business Addresses:** **Newport Coast Center for Digestive, Liver & Pancreaticobiliary Disorders**  
1525 Superior Avenue, Suite 200  
Newport Beach, CA 92663  
Phone: (949)650-0506  
FAX: (949)650-0044  
Cell: (949)887-9928  
E mail: [linodeguzman@gmail.com](mailto:linodeguzman@gmail.com)

**Western Gastroenterologists**  
15775 Laguna Canyon Road, Suite 200  
Irvine, CA 92618  
Phone: (949)727-1232  
FAX: (949)650-0044

Citizenship: United States

**EMPLOYMENT HISTORY**

**Private Practice in Gastroenterology and Hepatology**

3/2008-present Newport Coast Center for Digestive, Liver & Pancreaticobiliary Disorders  
10/2007-present Western Gastroenterologists, Irvine, CA  
1999-February 2008 Inland Empire Digestive Diseases and Liver Center, Redlands, CA  
  
2000-2002 Chairman, Department of Internal Medicine  
Arrowhead Regional Medical Center, Colton, CA  
*Formerly, San Bernardino County Medical Center  
San Bernardino, CA*  
  
1994-2002 Director, Section of Gastroenterology  
Department of Internal Medicine  
Arrowhead Regional Medical Center, Colton, CA

**ACADEMIC APPOINTMENTS**

1996-present Assistant Clinical Professor of Medicine  
Loma Linda University Medical Center, Loma Linda, CA

**LINO J. DeGUZMAN, M.D.**  
**Page 2 of 13**

**EDUCATION AND TRAINING**

## **Post-Graduate**

1993-94	Division of Gastroenterology University of Illinois at Chicago Chicago, Illinois Chief: Thomas J. Layden, M.D.	Chief Fellow Therapeutic Endoscopy/ ERCP/EUS Rama Venu, M.D.
1991-93	Division of Gastroenterology University of Illinois at Chicago, Chicago, Illinois Chief: Thomas J. Layden, M.D.	Fellow GI/Hepatology
1987-90	Department of Internal Medicine University of Medicine and Dentistry at New Jersey St. Barnabas Medical Center Livingston, New Jersey Chief: Richard Panush, M.D.	Resident PGY I,II,III

## **Graduate**

1982-86	University of Santo Tomas Faculty of Medicine & Surgery Manila, Philippines	M.D.
1986-87	University of Southern California School of Medicine Los Angeles County-USC Medical Center	Additional Clerkships

## **Undergraduate**

1977-82	University of Southern California School of Letters, Arts and Sciences Los Angeles, California	Bachelor of Arts (A.B.) Dean's List
---------	--	--

## **SOCIETIES**

American College of Gastroenterology  
American Gastroenterologic Association  
American Society for Gastrointestinal Endoscopy  
Philippine Medical Association of Southern California  
Southern California Society of Gastroenterology

**LINO J. DeGUZMAN, M.D.**  
**Page 3 of 13**

## **CERTIFICATION AND LICENSURE**

FLEX and FMGEMS  
Illinois State License: 036-082593  
California State License: A46594

DEA: BD2120068  
Diplomate of Gastroenterology, American Board of Internal Medicine  
State of California Fluoroscopy License  
Certificate of Good Clinical Practice Regulations & Guidelines in Research

### **GUEST SPEAKER**

- National Speaker for Schering Plough Corporation, Wyeth Ayerst, TAP and Jansenn
- GI Grand Rounds Guest Speaker at Royal Perth Hospital on January 6, 1997  
“Current Concepts in the Diagnosis & Management of Chronic Hepatitis C Infection,” Perth, Western Australia.
- California Society for Clinical Laboratory Sciences, March, 1997, University of California at Riverside, California.
- University of Santo Tomas Medical Alumni Association CME Speaker  
“Interpretation of Liver Enzyme Abnormalities: Practical Tips for the Primary Care Physician,” May 1996, Los Angeles, California.
- Expert Panel Speaker at the 12<sup>th</sup> Annual Dr. Robert H. Joseph Memorial Lecture  
“Management Options for Chronic Hepatitis C Infection,” October 14, 1997 at the University of California at Riverside, California.
- Feature article in the Press Enterprise for Riverside on October 21, 1997 entitled  
“Hepatitis C: possible epidemic”
- Primary CME Speaker at the San Bernardino Medical Society on October 23, 1997  
“Hepatitis C,” San Bernardino, CA
- Faculty, Alimentary Disease Week Manila, Philippines November 22-25, 1998  
“Screening and Diagnosis of Chronic Hepatitis C,” “Will Induction Dosing Influence Response?” and “Should We Treat Patients with Normal or Near-Normal ALT?”
- Faculty, U.S. Rebetrone Investigator’s Meeting, Palm Springs, February 4-7, 1999  
“Induction Dosing Using Intron-A”
- Moderator, “Optimizing Treatment for Chronic Hepatitis C, A Satellite Symposium,” Mission Inn, Riverside, CA, January 23, 2001.
- Faculty, “Integrative Approach to Chronic Disease,” University Medical Center, Las Vegas, NV, June 9, 2001.
- Faculty, “5<sup>th</sup> California Inter-County HCV Task Force Conference,” Mission Inn Hotel, Riverside, CA, April 7-8, 2006
- Faculty, Southern California Gastroenterology Nurses Association, Speaker in Pasadena, San Diego and Costa Mesa, CA, 2011 and 2012.
- Faculty, St. Luke’s 4th Liver and 2nd Gastroenterology International Symposium, Manila, Philippines, June 1-2, 2013.

**LINO J. DeGUZMAN, M.D.**

**Page 4 of 13**

### **COMMITTEES**

**1997-2002** Credentials Committee Member, Arrowhead Regional Medical Center (ARMC)

**1997-2002** Institutional Review Board Member, ARMC

**2000-2002** Medical Executive Committee, ARMC

### **AWARDS**

Alumni of the Year, University of Santo Tomas, Faculty of Medicine and Surgery  
September 2012

One of “Seven Outstanding Alumni for the Past 60 years,” University of Santo Tomas Medical Alumni Foundation, May 22, 1999.

Outstanding Young Physician Award, Philippine Medical Association of  
Southern California, April 25, 1998.

Dean's List, Univ of Southern California Letters Arts and Sciences 1978-82

## **PUBLICATIONS - Articles**

1. Lam N, **DeGuzman LJ**, Pitrak D, and Layden TJ. Clinical and histologic predictors of response to alpha-interferon in patients with chronic hepatitis C viral infection. *Digestive Diseases and Sciences*, 39, No. 12: 2660-2664, 1994.
2. **DeGuzman LJ**, Dawson G, Holzer T, Pitrak D, Shin D, and Layden TJ. Diagnosis of acute hepatitis E infection utilizing enzyme immunoassay. *Digestive Diseases and Sciences*, 39 (8):1691-1693, 1994.
3. Etzkorn KP, **DeGuzman LJ**, Schlesinger PK, Abu-Hammour A, and Watkins JL. Endoscopic drainage of pancreatic pseudocysts: Evaluation of outcome by endoscopic ultrasound. *Endoscopy*, 27: 329-333, 1995.
4. **DeGuzman LJ**, Nyhus LM, Yared G, and Schlesinger PK. Colocutaneous fistula formation following polypropylene mesh placement for repair of a ventral hernia. *Endoscopy*, Vol. 27, No. 6: 459-461, 1995.
5. **DeGuzman LJ**, Hibbeln J, and Watkins JL. An unusual migratory complication of a percutaneous gastrostomy tube retrieved by percutaneous needle puncture. *American Journal of Gastroenterology*, 88(12):2114-2115, 1993.
6. Glaws WR, **DeGuzman LJ**, Etzkorn KP, Steiner S, Vitello JM, Resnick DJ, and Watkins JL. Endoscopic treatment of biliary injuries associated with laparoscopic cholecystectomy: The University of Illinois Experience. *Chicago Medicine*, Vol. 97, No. 12: 20-25, 1994.
7. Watkins JL, **DeGuzman LJ**, Wiley TE, Etzkorn KP, and Harig JM. Assessment of technical competence during ERCP training. *Gastrointestinal Endoscopy*, Vol. 44, No. 4: 411-415, 1996.

**LINO J. DeGUZMAN, M.D.**

**Page 5 of 13**

8. Kovacs BJ, Chen YK, Lewis TD, **DeGuzman LJ** and Thompson KS. Successful Reversal of Barrett's Esophagus with Multipolar Electrocoagulation Despite Inadequate Acid Suppression. *Gastrointestinal Endoscopy* Vol 49, No. 5, 547-553, 1999.
9. Chen YK, Jajodia P, **DeGuzman L**, Khan S and Jakribettuu VS. Randomized Controlled Trial Comparing Proton Pump Inhibitor-Based Eradication Regimen versus Low-Cost Eradication Regimen for Patients with *Helicobacter pylori* with Uninvestigated Dyspepsia. *The Journal of Applied Research* Vol 6, No. 3, 2006.
10. Chen YK, **DeGuzman LJ**, Chang K and Godil A. Comparison of Endoscopic Sphincter Dilation Vs. Sphincterotomy for the Extraction of Bile Duct Stones:

**Oral Presentation**

1. Kovacs BJ, Chen YK, Lewis TD, **DeGuzman LJ**, Thompson KS, Walter MH and Griffin RA. Reversal of Barrett's Esophagus with Multipolar Electrocoagulation: Is Acid Suppression Important? (Presented at the American Gastroenterological Association Annual Meeting, Washington D.C., May 12-14, 1997.)
2. **DeGuzman LJ**, Hansen K and Hassanein TI. Induction therapy with interferon alpha-2b induces rapid clearance of hepatitis C viremia. (Presented at the 11th Biennial Scientific Meeting of the Asian Pacific Association for the Study of the Liver, Perth, Western Australia, February 16-20, 1998.)
3. Hassanein TI, Monson P, Chatfield ER, **DeGuzman LJ** and El-Mola TM. High ANA Levels Do Not Preclude Interferon Therapy in Patients with Chronic Hepatitis C Infection. (Presented at the 63<sup>rd</sup> Annual Scientific Meeting, American College of Gastroenterology, October 12-14, 1998.)
4. **LJ DeGuzman**, JM Nieto, SA DeGuzman, A Conrad and B Collins. Plasma Hepatitis C Virus (HCV) RNA is Comparable to Hepatic HCV RNA When Obtained While on Therapy at the End of Treatment as a Predictor of Sustained Response in Patients with Chronic Hepatitis C Infection. (Presented at the Annual Meeting, American Gastroenterological Association, Atlanta, GA, May 21, 2001.)

**Poster Presentation**

1. **DeGuzman LJ**, Etzkorn KP, and Watkins JL. Endoscopic ultrasonography: A universal computer database modified from the endoscopy database (Formerly ASGE Database). Presented at the American Gastroenterological Association Annual Meeting, New Orleans, LA, May 15-18, 1994.

**LINO J. DeGUZMAN, M.D.**

**Page 6 of 13**

2. **DeGuzman LJ**, Etzkorn KP, and Watkins JL. Hemangiopericytoma: An unusual case of obstructive jaundice. (Presented at the American College of Gastroenterology, San Francisco, CA, Sept. 28-29, 1994).
3. Lam N, **DeGuzman LJ**, Pitrak D, and Layden TJ. Predictors of response to alpha-interferon in patients with chronic hepatitis C: Correlation with pre-treatment clinical characteristics and liver biopsy results. (Presented at the United European Gastroenterology Week, Barcelona, Spain, 1993).
4. Watkins JL, **DeGuzman LJ**, Wiley TE, and Harig JM. Assessment of technical competence during ERCP training. (Presented at the American College of Gastroenterology in New York, New York, 1993).
5. Etzkorn KP, **DeGuzman LJ**, Abu-Hammour A, Harig JM, Holderman WH, and Watkins JL. Endoscopic drainage of pancreatic pseudocysts: Patient selection and evaluation of outcome by endoscopic doppler ultrasonography. (Presented as at the

American College of Gastroenterology Annual Meeting, San Francisco, CA, Sept. 28-29, 1994).

6. Abu-Hammour A, Etkorn KP, Venu RP, Wiley TE, **DeGuzman LJ**, Harig JM Watkins JL. Acute gallstone pancreatitis: New guidelines for ERCP prior to laparoscopic cholecystectomy. (Presented at the World Congress of Gastroenterology, Los Angeles, CA, Oct. 2-7, 1994)
7. Bartolone C, **DeGuzman LJ**, Glaws WR, Etkorn KP, and Watkins JL. Gastrointestinal bleeding from lung cancer metastasis to the small intestine. (Presented as a poster at the American College of Gastroenterology, San Francisco, CA, Sept. 28-29, 1994).
8. Etkorn KP, Abu-Hammour A, **DeGuzman LJ**, and Watkins JL. Amebic liver abscess complicated by biliary leak. (Presented at the American College of Gastroenterology, San Francisco, CA, Sept. 28-29, 1994).
9. Willis PW, **DeGuzman LJ**, and Chen C. Criteria to determine admission level of care for gastrointestinal hemorrhage. (Presented as a poster (#454) at the American College of Gastroenterology, Seattle, WA, Oct. 21-23, 1996); ACG, Vol 91, No. 9, Sept 1996.
10. Hassanein TI, Bell L and **DeGuzman LJ**. High-dose interferon alpha 2-b is highly effective and well tolerated in both naive and previously treated patients with chronic hepatitis C infection from Southern California. (Presented at the 4<sup>th</sup> International Meeting on Hepatitis C Virus and Related Viruses, Kyoto, Japan, March 6-10, 1997).

**LINO J. DeGUZMAN, M.D.**

**Page 7 of 13**

11. Hassanein TI and **DeGuzman LJ**. High-dose interferon-alpha 2b is highly effective and well tolerated especially in naive patients when compared to previously treated patients with chronic hepatitis C infection. (Presented at the AASLD Single Topic Symposium, Tysons Corner, Virginia, June 27-28, 1997).
12. McCarter TL, Godil A, **DeGuzman LJ**, Schilling RC, Lewis TD, Walter MH and Chen YK. Prospective comparison of patients with stress ulcer bleeding versus nonstress ulcer (peptic) bleeding. (Presented as a poster (#143) at the American College of Gastroenterology, November 1997); ACG, Vol 92, No. 9, Sept 1997.
13. Rond R, Hansen K, **DeGuzman LJ**, Venkataramani A, Lee D and Hassanein T. Combination therapy in Interferon Non-Responders: Induction Protocol (Interim Report). U.S. RebetoI Investigators Meeting, January 29-31, 1998, Puerto Rico.
14. Godil A, **DeGuzman L**, McCarter TL, Schilling RC, Khan SA, Lewis TD and Chen YK. Stress ulcer versus non-stress ulcer: Clinical outcome of ulcer bleeding depends on underlying etiology. (Presented as a poster (#G574) at the American Gastroenterologic Association Annual Meeting, May 18-19, 1998, New Orleans, LA); Gastroenterology, Vol 114, No. 4, Pt. 2, April 1998.

15. Chen YK, **DeGuzman L**, Godil A, Chang KJ, Erickson RA and Walter MH. Prospective randomized trial of endoscopic balloon dilation versus sphincterotomy for extraction of bile duct stones. (Presented as a poster (#347) at the American Society for Gastrointestinal Endoscopy Annual Meeting, May 20-21, 1998, New Orleans, LA); ASGE Vol. 47, No. 4, April 1998.
16. Godil A, **DeGuzman L**, Schilling RC, Khan SA and Chen YK. Recent NSAID use increases risk of early rebleeding in patients presenting with bleeding ulcer. (Presented as a poster (#239) at the American Society for Gastrointestinal Endoscopy Annual Meeting, May 20-21, 1998, New Orleans, LA); ASGE Vol. 47, No. 4, April 1998.
17. **DeGuzman LJ**, Chan DC, Huang SM, Hassanein TI, Hanson K and Leckemby DL. induction therapy with interferon alpha-2b increases clearance of hepatitis C viremia in naïve patients. (Presented at the American Association for the Study of Liver Diseases, November 4-6, 1998, Chicago, Illinois); Hepatology, Vol. 28, No. 4, Pt 2, Oct 1998.
18. Hassanein TI, Monson P, Nguyen TT, **DeGuzman LJ**, Lyche KD, Chatfield ER, Hanson K, Rond RL, El-Mola TM and Hardison WG. In HCV non-responders: Combination therapy is more effective than induction therapy in achieving viral clearance. (Presented as a poster (#1633) at the American Association for the Study of Liver Diseases, November 4-6, 1998, Chicago, Illinois); Hepatology, Vol. 28, No. 4, Pt 2, Oct 1998.

**LINO J. DeGUZMAN, M.D.**

**Page 8 of 13**

19. Huang SM, **DeGuzman LJ**, Chan DC, Hassanein TI and Lawson T. Iron saturation levels may predict response to induction dose interferon therapy in patients with chronic hepatitis C infection. (Presented as a poster (#1660) at the American Association for the Study of Liver Diseases, November 4-6, 1998, Chicago, Illinois); Hepatology, Vol. 28, No. 4, Pt 2, Oct 1998.
20. Hassanein TI, Monson P, **DeGuzman LJ**, Nguyen TY, Lyche KD, Chatfield ER, Hanson, K, Rond RL, El-Mola TM and Hardison WG. In HCV relapsers: Induction Course of interferon alpha-2b improved the response to combination therapy. (Presented as a poster (#1664) at the American Association for the Study of Liver Diseases, November 4-6, 1998, Chicago, Illinois); Hepatology, Vol. 28, No. 4, Pt 2, Oct 1998.
21. **DeGuzman LJ**, Chan SM, Dickinson O, Querol C and Velazquez N. Randomized trial comparing the efficacy of induction dose Intron-A followed by combination Intron-A plus ribavirin in previously treated patients with chronic hepatitis C (HCV) infection. (Presented at the U.S. Rebetrone Investigators Meeting, February 4-7, 1999, Palm Springs, CA).
22. **DeGuzman LJ**, Dickinson O, Chan S, Velazquez N and Querol C. Will induction dosing with interferon alpha-2b influence sustained response in naïve patients with chronic hepatitis C infection? (Presented at the U.S. Rebetrone Investigators Meeting, February 4-7, 1999, Palm Springs, CA).

23. **LJ DeGuzman**, JM Nieto and FR Loberiza. Early Viral Clearance at One Month and Three Months is Highly Predictive of Sustained Response During Induction Dose Interferon Alpha-2b Therapy for Chronic Hepatitis C (HCV) Infection. Presented at the Annual Meeting for the American Association for the Study of Liver Diseases, [Poster #401], November 1999, Dallas, Texas (**Presidents' Choice Award**); Hepatology, Vol. 30, No. 4, Pt 2, Oct 1999.
24. **LJ DeGuzman**, JM Nieto, JR Evans, M Parikh and D Leckemby. The Mucosal Clip Assisted Method (MCAM) for the Placement of Percutaneously Placed Jejunal Enteral Tubes (JET/PEG) is Safe and Effective. (Presented as a poster (#4740) at the American Gastroenterologic Association Annual Meeting, May 21-24, 2000, San Diego, CA). Gastrointestinal Endoscopy, Vol. 51, No. 4, part 2, April 2000.
25. **LJ DeGuzman**, JM Nieto, D Leckemby, C Calip and EK Onuma. Randomized Trial Comparing the Efficacy of the Mucosal Clip Assisted Method (MCAM) vs the Standard Pull Method (SPM) for the Placement of Percutaneously Placed Jejunal Enteral Tubes. (Presented at the American College of Gastroenterology Annual Meeting, [Poster #282] October 2000, New York, NY). AJG, Vol 95, No. 9, Sept 2000.

**LINO J. DeGUZMAN, M.D.**  
**Page 9 of 13**

26. **LJ DeGuzman**, JM Nieto, WN Schmidt, C Calip and A Conrad. Hepatitis C Virus (HCV) RNA in Plasma and Not Peripheral Blood Mononuclear Cells (PBMC) is Comparable to Hepatic HCV RNA When Obtained While on Therapy at the End of Treatment as a Predictor of Sustained Response in Patients with Chronic Hepatitis C Infection. (Presented at the Annual Meeting [Poster #780], American Association for the Study of Liver Diseases, November 2000, Dallas, TX). Hepatology, Vol. 32, No. 4, Pt. 2, October 2000.
27. **LJ DeGuzman** and BD Collins. Three Month HCV RNA by PCR Post IFN and Ribavirin Therapy for Successfully Treated Chronic Active Hepatitis C can be used To Determine Sustained Virological Response (SVR). (Presented at the Annual Meeting [Poster # 1903]. American Association for the Study of Liver Diseases, October 2004, Boston, MA). Hepatology, Vol. 40, No. 4, Supplement 1, Oct. 2004.

### Abstracts

1. **DeGuzman LJ**, Mehta MI, Mogan GR, Sloan WC, and Rickert RR. Crohn's disease of the vulva antedating gastrointestinal involvement. [Abstract] American Journal of Gastroenterology, Vol. 89, No. 9, 1994.
2. **DeGuzman LJ** and Watkins JL. Schwannoma of the colon. [Abstract] American Journal of Gastroenterology, Vol. 89, No. 9, 1994.
3. Lam N, **DeGuzman LJ**, Pitrak D, and Layden TJ. Clinical and histologic predictors of response to alpha-interferon in patients with chronic hepatitis C viral infection [Abstract] Gastroenterology, 106:A923, Apr.-June, 1994.

4. Wiley TE, **DeGuzman LJ**, Watkins JL, and Layden TJ. An unusual combination of primary sclerosing cholangitis and hepatocellular carcinoma. [Abstract] American Journal of Gastroenterology, Vol. 89, No. 9, 1994.
5. **DeGuzman LJ**, Evans RJ. Endoscopic treatment of benign extra-esophageal gastrointestinal tract strictures via combined pneumatic dilation and intralesional steroid injection. [Abstract #235] Gastrointestinal Endoscopy, Vol. 43, No. 4, April 1996.
6. Lanum D, Evans JR and **DeGuzman LJ**. Post-ERCP pancreatitis following monitored anesthesia care. [Abstract #415] Gastrointestinal Endoscopy, Vol 45, No. 4, April 97.
7. **DeGuzman LJ**, Bell L and Hassanein TI. Tolerance and complications of daily high-dose interferon alpha 2-b. [Abstract #1254] Gastroenterology Vol 112, No. 4, April 97.

**LINO J. DeGUZMAN, M.D.**

**Page 10 of 13**

8. Hassanein T, **DeGuzman LJ** and Bell L. High-dose interferon alpha 2-b is more effective in achieving viral negativity in both naïve patients and previous non-responders with chronic hepatitis C infection. [Abstract #1279] Gastroenterology Vol 112, No. 4, April 97.
9. Higa L, Katkov W, **DeGuzman L**, Peacock V, Dewan P, Dao M, Getzing T, Stribling R and Martin P. A 12 month randomized trial of initial higher dose interferon alpha 2-b followed by constant or tapered dosing in the treatment of chronic hepatitis C. [Abstract #1283] Gastroenterology Vol 112, No 4, April 97.
10. Hassanein T and **DeGuzman LJ**. Induction therapy with interferon alpha-2b induces rapid clearance of hepatitis C viremia in naive patients. [Abstract #1572] Hepatology Vol. 26, No. 4, Pt 2 (November 1997).
11. **DeGuzman LJ** and Hassanein T. Induction therapy with interferon alpha-2b induces rapid clearance of hepatitis C viremia in relapsers. [Abstract 1473] Hepatology Vol. 26, No. 4, Pt 2 (November 1997).
12. Rond R, Hansen K, **DeGuzman LJ**, Venkataramani A, Lee D and Hassanein T. Combination therapy in Interferon Non-Responders: Induction Protocol (Interim Report U.S. Rebetrone Investigators Meeting, 1998).
13. SM Huang, **LJ DeGuzman**, DC Chan, TI Hassanein and T. Lawson. Iron Saturation Levels May Predict Response to Induction Dose Interferon Therapy in Patients with Chronic Hepatitis C Infection (#1660). Hepatology Vol.28, No.4, Pt 2 (November 1998).
14. **LJ DeGuzman**, SM Huang, DC Chan and C Querol. Should Chronic Hepatitis C Patients with Normal or Near-Normal ALT Be Treated with Interferon? Review of Data Using Induction Dose Interferon(#2207). Hepatology Vol.28, No.4, Pt 2

(November 1998).

15. **LJ DeGuzman**, DC Chan, SM Huang, TI Hassanein, K Hanson and DL Leckemby. Induction Therapy with Interferon Alpha-2b Increases Clearance of Hepatitis C Viremia in Naïve Patients (#2440). Hepatology Vol.28 , No.4, Pt 2 (November 98).
16. Hassanein T, **DeGuzman LJ**, Monson P, El-Mola TM, Hanson K, Chatfield ER and Hart ME. Prolonged HCV-suppression using daily interferon alfa increases the sustained response in naïve patients (#2201). Hepatology Vol.28 , No.4, Pt 2 (November 1998).

**LINO J. DeGUZMAN, M.D.**

**Page 11 of 13**

17. **DeGuzman LJ** , E Carter, S Chen, J Nieto, K Yahya, B Collins and E Onuma, Intron-A + Ribavirin (Rebetron ) and Induction Intron-A + Ribavirin is More Effective Than Induction Intron-A Alone Followed by Combination Rebetron for the Treatment of Naive Chronic Hepatitis C (HCV) Patients. A Multicenter Randomized Trial. SHINE Meeting, Orlando, FLA February 2001.
18. **DeGuzman LJ**, ST Chen, D Phillips, J Nieto, EA Galen, JJ Jolley and K Yahya. Randomized Multicenter Trial Comparing the Efficacy of Induction Dose Intron-A Plus Ribavirin and Amantadine vs Induction Dose Intron-A Plus Ribavirin in Previously Treated Patients with Chronic Hepatitis C Infection. SHINE Meeting, Orlando, FLA February 2001.
19. **DeGuzman LJ**, JM Nieto, SA DeGuzman, A Conrad and B Collins. Plasma Hepatitis C Virus (HCV) RNA is Comparable to Hepatic HCV RNA When Obtained While on Therapy at the End of Treatment as a Predictor of Sustained Response in Patients with Chronic Hepatitis C Infection. Gastroenterology Vol 120, No. 5, Suppl 1, April 2001.

#### **Prior Research Protocols**

1. “Factors Influencing the Natural History of Bleeding Peptic Ulcers”
2. “Controlled Trial of Interferon (IFN) Alfa-2B Therapy for Chronic Hepatitis C”
3. “Controlled Trial of Reversal of Barrett’s Esophagus with Acid Suppression and Multi-Polar Electrocoagulation”
4. “The Role of Interferon Alpha-2b Therapy in Patients with Chronic Hepatitis C Infection Presenting with Normal or Near Normal Alanine Aminotransferase Levels”
5. “Randomized Trial of Patients with Chronic Hepatitis C Infections Who Failed to Respond to Alpha-Interferon with Iron Depletion Therapy Using Standard Dose vs. Sliding Scale High Dose Alpha-Interferon”

6. "A Prospective Multicentered, Randomized Trial Using Vitamin E and N-Acetylcysteine Therapy for the Treatment of Alcoholic Hepatitis"
7. "Treatment of Patients with Chronic Hepatitis C Infection with Sliding Scale of Interferon"
8. "Comparison of Endoscopic Sphincter Dilation Vs. Sphincterotomy for the Extraction of Bile Duct Stones: A Randomized, Prospective Study"

**LINO J. DeGUZMAN, M.D.**  
**Page 12 of 13**

9. "Positive Fecal Occult Blood Test Found on Digital Rectal Examination: Correlation with Results of Take-Home Fecal Occult Blood Tests and Findings at Colonoscopy"
10. "Intron A + Ribavirin for the Treatment of Patients with Interferon-Refractory or Interferon-Relapsed Chronic Hepatitis C"
11. "Intron-A plus Ribavirin for Treatment of Patients with Chronic Hepatitis C Not Previously Treated with Interferon"
12. "Controlled Trial Using Intron-A for the Treatment of Chronic Hepatitis C Infection in Patients with Psychiatric Disorders"
13. "Randomized Study Using Intron-A→ , Ribavirin plus Amantadine vs Intron-A→ Plus Ribavirin for the Treatment of Patients with Chronic Hepatitis C Who Were Prior Non-Responders to Interferon or Interferon Plus Ribavirin"
- 14.) "Randomized study of oral lobucavir vs. alpha interferon in subjects chronically infected with hepatitis B virus" (Discontinued by Bristol Myers).
- 15.) "A randomized, double-blind, placebo-controlled study of oral lobucavir in subjects chronically infected with hepatitis B virus" (Discontinued by Bristol Myers).
- 16.) "Multicenter, open-label, randomized study to compare the safety and efficacy of levofloxacin vs ceftriaxone and erythromycin followed by clarithromycin and amoxicillin/clavulanate in the treatment of serious community acquired pneumonia in adults" **Protocol CAPSS-018**
- 17.) "Comparative, double-blind, randomized, multicenter, parallel study of the efficacy and safety of oral HMR3647 (800 mg QD) for 7 to 10 days vs. trovafloxacin (200 mg QD) for 7 to 10 days in the treatment of community acquired pneumonia in adults" **Protocol HMR3647/3009**
- 18.) "Linezolid for the treatment of vancomycin-resistant enterococcal infections: a double-blind trial comparing 600 mg of linezolid every 12 hours with 200 mg linezolid every 12 hours" **Protocol M/1260/0054**
- 19.) "Dose Comparison Study of PEG-Interferon Alfa-2b + Ribavirin For Patients With Chronic Hepatitis C Who Have Not Responded To Standard Interferon + Ribavirin" *PI: John Gross, MD*

- 20.) “Comparison of PEG Interferon alfa-2b plus Ribavirin Given as a Fixed Dose Or on a Weight Optimized Basis for Treatment of Chronic Hepatitis C in Previously Untreated Adult Subjects” *PI: Ira Jacobson, MD*

**LINO J. DeGUZMAN, M.D.**

**Page 13 of 13**

- 21.) “Triple Therapy for Rebetrone Failure Patients with Hepatitis C” *PI: Bradley Freilich, MD*
- 22.) “A Multicenter Randomized Controlled Trial Evaluating PEG Intron + Rebetol for Genotype 1 Hepatitis C Patients with Normal Aminotransferase Levels : (The PING Trial)” *Co-PI's: Paul Kwo, MD and Lino DeGuzman, MD*
- 23.) “An Efficacy and Safety Study of Intravenous Pantoprazole in the Prevention of Recurrent Peptic Ulcer Bleeding After Successful Hemostasis”  
*Protocol # 3001K2-315US*
- 24) “A 12-Week, Randomized, Double Blind, Placebo, Controlled, Parallel Group Study to Assess the Safety and Efficacy of 0.5 mg QD and 1 mg QD and 1 mg BID of Alosetron in Female Subjects with Severe Diarrhea Predominance IBS Who Have Failed Conventional Therapy” *Protocol# S3B30040*
- 25) “A 6 Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study, to Assess the Efficacy and Safety of Oral Tegaserod (6 g bid) and Placebo in Female Patients with Dyspepsia.” *Project: HTF919D/ Study#:2302E1*
- 26) “Endoscopic Implantation of Enteryx for the Treatment of Symptomatic Gastroesophageal Reflux Disease (GERD).” *Protocol #320-1001*
- 27) “A Prospective, Multicenter, Open-Label, Comparative, Efficacy Study of Pegasys plus Copegus in Treatment-Naïve Latino Patients with Chronic Hepatitis C-Genotype 1, as Compared to Treatment-Naïve Non-Latino Caucasian Patients with Chronic Hepatitis C-Genotype 1.” *Protocol # ML18179*
- 28) “A Double-Blind, Randomized Controlled Trial of Rifaxim Compared to Vancomycin for the Treatment of Clostridium Dificile Associated Diarrhea.”  
*Protocol # RFCL3001*

**MEDICAL MISSIONS:**

**December 2006** Medical and Dental Mission in Boracay, Philippines  
**November 2008** GI Medical Mission specializing in ERCP and Advanced Endoscopy Procedures including lectures to GI Physicians in Hanoi and Hue, Vietnam.

**SPEAKER'S BUREAU**

Warner Chilcott Pharmaceuticals

Ironwood Pharmaceuticals  
Ferring Pharmaceuticals

*Revised 9-2013*